{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:56:24Z","timestamp":1792158984211,"version":"4.4.0"},"reference-count":81,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"12","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2026,10,16]]},"DOI":"10.1167\/iovs.67.12.31","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:30:35Z","timestamp":1792157435000},"page":"31","source":"Crossref","is-referenced-by-count":0,"title":["Individual-Eye Pharmacokinetics of Intravitreal Ranibizumab: Linking Ocular Geometry to Drug Retention Using MRI and Modeling"],"prefix":"10.1167","volume":"67","author":[{"given":"Patricia","family":"Lamirande","sequence":"first","affiliation":[{"name":"Wolfson Centre for Mathematical Biology, Mathematical Institute, Andrew Wiles Building, University of Oxford, Oxford, United Kingdom"},{"name":"Department of Mathematics and Statistics and Sainte-Justine University Hospital Azrieli Research Centre, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamonn A.","family":"Gaffney","sequence":"additional","affiliation":[{"name":"Wolfson Centre for Mathematical Biology, Mathematical Institute, Andrew Wiles Building, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gertz","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil","family":"K\u00fcnnecke","sequence":"additional","affiliation":[{"name":"Neuroscience and Rare Diseases, Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bielser","sequence":"additional","affiliation":[{"name":"Neuroscience and Rare Diseases, Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bruns","sequence":"additional","affiliation":[{"name":"Neuroscience and Rare Diseases, Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Crawshaw","sequence":"additional","affiliation":[{"name":"School of Mathematical Sciences, Queensland University of Technology, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Wessels","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Rampazzo","sequence":"additional","affiliation":[{"name":"Ophthalmology Section, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip K.","family":"Maini","sequence":"additional","affiliation":[{"name":"Wolfson Centre for Mathematical Biology, Mathematical Institute, Andrew Wiles Building, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Caruso","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"issue":"14","key":"bib1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1167\/iovs.62.14.26","article-title":"Retinal and choroidal vascular diseases: past, present, and future: the 2021 proctor lecture","volume":"62","author":"Campochiaro","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9827","key":"bib2","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"bib3","first-page":"99","article-title":"Common causes of vision loss in elderly patients","volume":"60","author":"Quillen","year":"1999","journal-title":"Am Fam Physician"},{"issue":"1","key":"bib4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"issue":"10153","key":"bib5","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"issue":"1185","key":"bib6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/postmj\/qgae016","article-title":"Advancements in the treatment of age-related macular degeneration: a comprehensive review","volume":"100","author":"Papaioannou","year":"2024","journal-title":"Postgrad Med J"},{"issue":"6 Suppl","key":"bib7","first-page":"S75","article-title":"Disease burden of neovascular age-related macular degeneration and diabetic macular edema","volume":"29","author":"Almony","year":"2023","journal-title":"Am J Manag Care"},{"issue":"2","key":"bib8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/eye.2015.217","article-title":"Ranibizumab for the treatment of wet AMD: a summary of real-world studies","volume":"30","author":"Chong","year":"2016","journal-title":"Eye"},{"issue":"3","key":"bib9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3109\/08820538.2010.541318","article-title":"Intravitreal injection technique","volume":"26","author":"Doshi","year":"2011","journal-title":"Semin Ophthalmol"},{"issue":"1","key":"bib10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"bib11","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/eye.2017.67","article-title":"A systematic review to assess the \u2018treat-and-extend\u2019 dosing regimen for neovascular age-related macular degeneration using ranibizumab","volume":"31","author":"Rufai","year":"2017","journal-title":"Eye (Lond)"},{"issue":"10","key":"bib12","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"issue":"2","key":"bib13","first-page":"695","article-title":"Ocular half-life of intravitreal biologics in humans and other species: meta-analysis and model-based prediction","volume":"17","author":"Caruso","year":"2020","journal-title":"Mol Pharm"},{"issue":"6","key":"bib14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/tvst.8.6.1","article-title":"Influence of charge, hydrophobicity, and size on vitreous pharmacokinetics of large molecules","volume":"8","author":"Crowell","year":"2019","journal-title":"Transl Vis Sci Technol"},{"issue":"12","key":"bib15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/iovs.65.12.21","article-title":"A first-passage model of intravitreal drug delivery and residence time\u2014influence of ocular geometry, individual variability, and injection location","volume":"65","author":"Lamirande","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"bib16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/IAE.0000000000000265","article-title":"Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors","volume":"35","author":"Krohne","year":"2015","journal-title":"Retina"},{"issue":"9","key":"bib17","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1097\/IAE.0b013e318217373c","article-title":"Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans","volume":"31","author":"Meyer","year":"2011","journal-title":"Retina"},{"issue":"4","key":"bib18","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"bib19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1167\/iovs.13-13054","article-title":"Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes","volume":"55","author":"Ahn","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"bib20","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"bib21","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/OPTH.S19555","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin\u00ae) in rabbits","volume":"5","author":"Sinapis","year":"2011","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"bib22","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1097\/IAE.0b013e318134eecd","article-title":"Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits","volume":"27","author":"Gaudreault","year":"2007","journal-title":"Retina"},{"issue":"9","key":"bib23","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1021\/acs.molpharmaceut.6b00345","article-title":"Contribution of antibody hydrodynamic size to vitreal clearance revealed through rabbit studies using a species-matched Fab","volume":"13","author":"Shatz","year":"2016","journal-title":"Mol Pharm"},{"issue":"9","key":"bib24","first-page":"2684","article-title":"Sympathetic nervous system plays a role in postnatal eyeball enlargement in the rabbit","volume":"41","author":"Liu","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"bib25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1159\/000145215","article-title":"Eye volume in young and adult rabbits","volume":"106","author":"Sarnat","year":"1980","journal-title":"Cells Tissues Organs"},{"issue":"3","key":"bib26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.acra.2005.10.023","article-title":"High-resolution MR imaging of the human eye 2005","volume":"13","author":"Bert","year":"2006","journal-title":"Acad Radiol"},{"issue":"6","key":"bib27","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3174\/ajnr.A6495","article-title":"MR-eye: high-resolution microscopy coil MRI for the assessment of the orbit and periorbital structures, part 1: technique and anatomy","volume":"41","author":"Dobbs","year":"2020","journal-title":"Am J Neuroradiol"},{"issue":"1","key":"bib28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12917-021-03108-0","article-title":"3T High-resolution magnetic resonance imaging, conventional ultrasonography and ultrasound biomicroscopy of the normal canine eye","volume":"18","author":"Ivan","year":"2022","journal-title":"BMC Vet Res"},{"issue":"5","key":"bib29","first-page":"924","article-title":"7 Tesla MR imaging of the human eye in vivo","volume":"30","author":"Richdale","year":"2009","journal-title":"J Magn Reson Imaging Off J Int Soc Magn Reson Med"},{"issue":"12","key":"bib30","first-page":"3109","article-title":"Magnetic resonance imaging of the rabbit eye. Improved anatomical detail using magnetization transfer contrast","volume":"32","author":"Ceckler","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"bib31","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ejmp.2015.03.009","article-title":"High resolution MR eye protocol optimization: comparison between 3D-CISS, 3D-PSIF and 3D-VIBE sequences","volume":"31","author":"Tsiapa","year":"2015","journal-title":"Phys Med"},{"issue":"10","key":"bib32","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1167\/iovs.04-0292","article-title":"Eye shape in emmetropia and myopia","volume":"45","author":"Atchison","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"bib33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1167\/iovs.64.4.24","article-title":"Age-dependent changes in the water content and optical power of the in vivo mouse lens revealed by multi-parametric MRI and optical modeling","volume":"64","author":"Pan","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"bib34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1076\/ceyr.25.3.173.13474","article-title":"Magnetic resonance imaging studies of the volume of the rabbit eye with intravenous mannitol","volume":"25","author":"Sawada","year":"2002","journal-title":"Curr Eye Res"},{"issue":"1","key":"bib35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/iovs.08-2767","article-title":"Analysis of postnatal eye development in the mouse with high-resolution small animal magnetic resonance imaging","volume":"51","author":"Tkatchenko","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1115\/1.2052828","article-title":"MRI guided 3D mesh generation and registration for biological modeling","volume":"5","author":"Zhang","year":"2005","journal-title":"J Comput Inf Sci Eng"},{"issue":"6","key":"bib37","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1167\/iovs.05-0856","article-title":"Three-dimensional modeling of the human eye based on magnetic resonance imaging","volume":"47","author":"Singh","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"bib38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1001\/archopht.1967.00980020126027","article-title":"A new system for visual axis measurements in the human eye using ultrasound","volume":"77","author":"Coleman","year":"1967","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"bib39","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1167\/iovs.09-4140","article-title":"Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes","volume":"51","author":"Miyake","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"bib40","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1167\/iovs.15-17279","article-title":"Ranibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes","volume":"56","author":"Niwa","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"bib41","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1136\/bjophthalmol-2015-306771","article-title":"A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab","volume":"99","author":"Saunders","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"bib42","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1021\/acs.molpharmaceut.5c00120","article-title":"Ocular kinetics, distribution, and effects of human VEGF isoforms 121 and 165: Implications for therapeutic intervention","volume":"22","author":"Caruso","year":"2025","journal-title":"Mol Pharm"},{"issue":"8","key":"bib43","doi-asserted-by":"publisher","first-page":"5899","DOI":"10.1167\/iovs.10-6862","article-title":"PET\/CT imaging of I-124\u2013radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit model","volume":"52","author":"Christoforidis","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"bib44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000525745","article-title":"Intravitreal tissue plasminogen activator injection for the treatment of proliferative vitreoretinopathy in a rabbit model","volume":"66","author":"Reitblat","year":"2022","journal-title":"Ophthalmic Res"},{"issue":"14","key":"bib45","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"bib46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40942-020-00235-y","article-title":"Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits","volume":"6","author":"Baiza-Dur\u00e1n","year":"2020","journal-title":"Int J Retina Vitr"},{"issue":"6","key":"bib48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1167\/iovs.66.6.20","article-title":"Modeling the ocular pharmacokinetics and pharmacodynamics of ranibizumab for improved understanding and data collection strategies in ocular diseases","volume":"66","author":"Crawshaw","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1984","key":"bib49","first-page":"20110544","article-title":"Joining forces of Bayesian and frequentist methodology: a study for inference in the presence of non-identifiability","volume":"371","author":"Raue","year":"2013","journal-title":"Philos Trans R Soc Math Phys Eng Sci"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"800856","DOI":"10.3389\/fmolb.2022.800856","article-title":"Optimal experimental design based on two-dimensional likelihood profiles","volume":"9","author":"Litwin","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"164","key":"bib51","doi-asserted-by":"publisher","first-page":"20200055","DOI":"10.1098\/rsif.2020.0055","article-title":"Practical parameter identifiability for spatio-temporal models of cell invasion","volume":"17","author":"Simpson","year":"2020","journal-title":"J R Soc Interface"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"110998","DOI":"10.1016\/j.jtbi.2021.110998","article-title":"Parameter identifiability and model selection for sigmoid population growth models","volume":"535","author":"Simpson","year":"2022","journal-title":"J Theor Biol"},{"issue":"9","key":"bib53","doi-asserted-by":"publisher","first-page":"e1011515","DOI":"10.1371\/journal.pcbi.1011515","article-title":"Profile-wise analysis: a profile likelihood-based workflow for identifiability analysis, estimation, and prediction with mechanistic mathematical models","volume":"19","author":"Simpson","year":"2023","journal-title":"PLoS Comput Biol"},{"issue":"212","key":"bib54","doi-asserted-by":"publisher","first-page":"20230607","DOI":"10.1098\/rsif.2023.0607","article-title":"Parameter identifiability and model selection for partial differential equation models of cell invasion","volume":"21","author":"Liu","year":"2024","journal-title":"J R Soc Interface"},{"issue":"4","key":"bib55","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11538-024-01266-4","article-title":"Parameter identifiability in PDE models of fluorescence recovery after photobleaching","volume":"86","author":"Ciocanel","year":"2024","journal-title":"Bull Math Biol"},{"issue":"5","key":"bib56","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"bib57","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/psp4.12611","article-title":"Approaches to handling missing or \u201cproblematic\u201d pharmacology data: pharmacokinetics","volume":"10","author":"Irby","year":"2021","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"1","key":"bib60","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/tvst.9.1.2","article-title":"In vivo measurement of the human vitreous chamber volume using computed tomography imaging of 100 eyes","volume":"9","author":"Azhdam","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"bib61","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00417-020-04991-3","article-title":"Use of axial length to estimate the vitreous chamber volume in pseudophakic","volume":"259","author":"de Santana","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"42","key":"bib62","doi-asserted-by":"publisher","first-page":"e22685","DOI":"10.1097\/MD.0000000000022685","article-title":"Quantitative analysis with volume rendering of pathological myopic eyes by high-resolution three-dimensional magnetic resonance imaging","volume":"99","author":"Zhou","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"bib63","first-page":"35","article-title":"Comparative study on ocular anatomical features among rabbits, beagle dogs and cynomolgus monkeys","volume":"32","author":"Atsumi","year":"2013","journal-title":"Anim Eye Res"},{"issue":"13","key":"bib64","first-page":"2796","article-title":"Twenty-four-hour change in axial length in the rabbit eye","volume":"39","author":"Liu","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"bib65","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1463-5224.2006.00495.x","article-title":"Experimental evaluation of ophthalmic devices and solutions using rabbit models","volume":"9","author":"Werner","year":"2006","journal-title":"Vet Ophthalmol"},{"issue":"1","key":"bib66","first-page":"9","article-title":"Measurements of axial length and radius of corneal curvature in the rabbit eye","volume":"51","author":"Bozkir","year":"1997","journal-title":"Acta Med Okayama"},{"issue":"1","key":"bib67","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0042-6989(72)90143-5","article-title":"A schematic eye for the rabbit","volume":"12","author":"Hughes","year":"1972","journal-title":"Vision Res"},{"issue":"4","key":"bib68","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000063123","article-title":"Dimensional growth of the rabbit eye","volume":"171","author":"Barathi","year":"2002","journal-title":"Cells Tissues Organs"},{"issue":"6","key":"bib69","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/vop.13209","article-title":"Ocular biometry in rabbits using computed tomography","volume":"27","author":"Goody","year":"2024","journal-title":"Vet Ophthalmol"},{"issue":"2","key":"bib70","doi-asserted-by":"publisher","first-page":"217","DOI":"10.18433\/J3FG63","article-title":"How critical is the duration of the sampling scheme for the determination of half-life, characterization of exposure and assessment of bioequivalence?","volume":"14","author":"Colucci","year":"2011","journal-title":"J Pharm Pharm Sci"},{"key":"bib71","first-page":"76","article-title":"Intravitreal clearance of moxifloxacin","volume":"103","author":"Iyer","year":"2005","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"Pt B","key":"bib72","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejpb.2015.01.003","article-title":"Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development","volume":"95","author":"del Amo","year":"2015","journal-title":"Eur J Pharm Biopharm Off"},{"issue":"9","key":"bib73","doi-asserted-by":"publisher","first-page":"e0310830","DOI":"10.1371\/journal.pone.0310830","article-title":"Anatomical and micro-CT measurement analysis of ocular volume and intraocular volume in adult Bama Miniature pigs, New Zealand rabbits, and Sprague-Dawley rats","volume":"19","author":"Wu","year":"2024","journal-title":"PLoS One"},{"issue":"9","key":"bib75","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1021\/acs.molpharmaceut.5b00849","article-title":"A mechanistic model of the intravitreal pharmacokinetics of large molecules and the pharmacodynamic suppression of ocular vascular endothelial growth factor levels by ranibizumab in patients with neovascular age-related macular degeneration","volume":"13","author":"Hutton-Smith","year":"2016","journal-title":"Mol Pharm"},{"issue":"11","key":"bib76","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1167\/tvst.13.11.14","article-title":"Ocular pharmacokinetics of faricimab following intravitreal administration in patients with retinal disease","volume":"13","author":"Diack","year":"2024","journal-title":"Transl Vis Sci Technol"},{"issue":"5","key":"bib77","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4155\/tde.11.19","article-title":"Flip-flop pharmacokinetics \u2013 delivering a reversal of disposition: challenges and opportunities during drug development","volume":"2","author":"Y\u00e1\u00f1ez","year":"2011","journal-title":"Ther Deliv"},{"issue":"4","key":"bib78","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.exer.2007.05.008","article-title":"Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo","volume":"85","author":"Lowe","year":"2007","journal-title":"Exp Eye Res"},{"issue":"2","key":"bib79","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"bib47","volume-title":"Modelling the Pharmacokinetics and Pharmacodynamics of Macromolecules for the Treatment of Wet AMD","author":"Hutton-Smith","year":"2018"},{"key":"bib58","article-title":"Monolix","author":"Simulations Plus"},{"key":"bib59","first-page":"193","article-title":"Chapter 7 Aqueous humor dynamics I: measurement methods and animal studies","volume-title":"Current Topics in Membranes","author":"Toris","year":"2008"},{"key":"bib74","first-page":"1","article-title":"Comparative ocular anatomy in commonly used laboratory animals","volume-title":"Assessing Ocular Toxicology in Laboratory Animals","author":"V\u00e9zina","year":"2013"},{"key":"bib80","author":"Australian Public Assessment Report for Ranibizumab"},{"key":"bib81","volume-title":"Lucentis (Ranibizumab) Label","author":"U.S. Food and Drug Administration","year":"2024"}],"container-title":["Investigative Ophthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.67.12.31","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:30:39Z","timestamp":1792157439000},"score":1,"resource":{"primary":{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.67.12.31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":81,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.67.12.31","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,16]]}}}